Laurus Labs inks agreement with MPP for manufacturing Molnupiravir

Laurus Labs Limited a leading research & development-driven, fully integrated pharmaceutical and biotech company in India signs an agreement with MPP (Medicine Patient Pool) for the manufacturing of the oral COVID-19 antiviral medication Molnupiravir.

Commenting on the development, Dr.Satyanarayana Chava, Founder and CEO, Laurus Labs said, "We are happy to sign an agreement to manufacture the oral Covid-19 antirviral medication, which is an urgent need of the hour, this is one of the most critical step towards fighting the pandemic and we are happy to contribute to the mission."

Shares of Laurus Labs Limited was last trading in BSE at Rs. 485.45 as compared to the previous close of Rs. 497.35. The total number of shares traded during the day was 102766 in over 3440 trades.

The stock hit an intraday high of Rs. 499.20 and intraday low of 482.00. The net turnover during the day was Rs. 50312305.00.

Source : Equity Bulls

Keywords

LaurusLabs INE947Q01028 Agreement MPP Molnupiravir